Lakhi Sakhrani, MD
Nephrology · Alhambra, CANPI 1518913037
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Mannkind Corporation at 29.3% of the total.
Across 162 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$866
- Fresenius USA Marketing, Inc.$350
- Bayer$318
- Novartis$237
- Aurinia Pharma U.S., Inc.$232
- Otsuka America Pharmaceutical, Inc.$195
- plus $761 from 14 others
Across 42 payments — averaging $351.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$13K
- Astrazeneca UK Limited$1K
What the payments were for
- Food & beverage$2,80495%
- Education$1555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 63 | $866 |
| Fresenius USA Marketing, Inc. | 18 | $350 |
| Bayer | 15 | $318 |
| Novartis | 9 | $237 |
| Aurinia Pharma U.S., Inc. | 10 | $232 |
| Otsuka America Pharmaceutical, Inc. | 5 | $195 |
| Amgen(2 entities) | 5 | $101 |
| Travere Therapeutics, Inc. | 8 | $100 |
| Calliditas Therapeutics US Inc. | 6 | $97 |
| Ardelyx, Inc. | 4 | $76 |
| GSK | 4 | $63 |
| Vifor Pharma, Inc. | 3 | $57 |
| Scpharmaceuticals Inc. | 2 | $52 |
| Lilly USA, LLC | 2 | $45 |
| OPKO Pharmaceuticals, LLC | 2 | $38 |
| AstraZeneca | 2 | $31 |
| Boehringer Ingelheim | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Novo Nordisk | 1 | $23 |
How this compares
$2,958 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 154 | $538,730 |
| ProcritEpoetin Alfa | 324 | $354,027 |
| FarxigaDapagliflozin Propanediol | 546 | $351,031 |
| FilspariSparsentan | 21 | $250,985 |
| JardianceEmpagliflozin | 365 | $226,772 |
| LokelmaSodium Zirconium Cyclosilicate | 180 | $141,120 |
| XphozahTenapanor Hcl | 31 | $116,204 |
| JanuviaSitagliptin Phosphate | 151 | $96,866 |
| KerendiaFinerenone | 138 | $95,875 |
| VeltassaPatiromer Calcium Sorbitex | 85 | $95,429 |
| AfrezzaInsulin Regular, Human | 39 | $87,445 |
| Cinacalcet Hcl | 139 | $63,422 |
| DapagliflozinDapagliflozin Propanediol | 81 | $44,385 |
| RenvelaSevelamer Carbonate | 30 | $41,305 |
| Sevelamer Carbonate | 211 | $40,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $350 | $538,730154 claims |
| AstraZenecaFarxiga, Lokelma, Crestor | $31 | $495,411738 claims |
| Travere Therapeutics, Inc.Filspari | $100 | $250,98521 claims |
| Boehringer IngelheimJardiance, Tradjenta | $28 | $234,692381 claims |
| BayerKerendia | $318 | $95,875138 claims |
| Mannkind CorporationAfrezza | $866 | $87,44539 claims |
| Sanofi-aventis U.S. LLCRenvela | $28 | $41,30530 claims |
| AmgenProlia | $101 | $18,62311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,341 nephrology providers in California.
Other nephrology in Alhambra
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.